Cue Health Inc.
Cue Health sells COVID-19 tests for home use and other tests to diagnose other diseases.
We are a health technology company, and our mission is to enable personalized, proactive and informed healthcare that empowers people to live their healthiest lives. Digital transformation has revolutionized nearly every industry except healthcare to create new, consumer-first experiences that are both personalized and empowering. We seek to usher in a new era in healthcare, what we call Healthcare 2.0, to transform how acute and chronic conditions are diagnosed and managed.
We believe the current healthcare system is challenged. Care delivery can often be uncontextualized and disconnected in an increasingly personalized and connected world. The vast majority of healthcare delivery still relies on in-person encounters at centralized locations while consumers and caregivers may often be forced to make important health decisions without complete or real-time information.
(Note: Cue Health priced its IPO on Sept. 23, 2021, at $16 – the mid-point of its $15-to-$17 range – and priced 12.5 million shares, the same number of shares in the prospectus, to raise $200 million.)
|Industry:||COVID-19 Home Tests & Digital Health Platform|
|Address||4980 Carroll Canyon Rd. Suite 100 San Diego, CA 92121|
|Phone Number||(858) 412-8151|
|View Prospectus:||Cue Health Inc.|
|Revenues||$219.85 mil (last 12 months)|
|Net Income||$4.77 mil (last 12 months)|
|Price range||$16.00 - $16.00|
|Est. $ Volume||$200.0 mil|
|Manager / Joint Managers||Goldman Sachs/ Morgan Stanley/ Cowen and Company|
|Expected To Trade:||9/24/2021|
|Quiet Period Expiration Date:||Available only to Subscribers|
|Lock-Up Period Expiration Date:||Available only to Subscribers|
|SCOOP Rating||Available only to Subscribers|
|Rating Change||Available only to Subscribers|